Physician profile
Albert E Raizner
NPI 1457342669
$3,180.08
in general payments reported to CMS, 2019-2025
24 companies · $259 in 2025
The $259 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $263 · 2021: $539 · 2022: $577 · 2023: $454 · 2024: $470 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,183.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $387.60 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $373.92 | 2019-2025 | Camzyos, Eliquis |
| Bolton Medical INC | $370.22 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $355.68 | 2020-2025 | |
| Abbott Laboratories | $313.89 | 2019-2024 | Jot Dx, Confirm Rx, Cardiomems |
| Abiomed | $307.10 | 2019 | |
| Amgen INC. | $186.60 | 2021-2025 | Repatha |
| Medtronic, INC. | $137.00 | 2024-2025 | Linq II, Hawkone |
| Boston Scientific Corporation | $116.85 | 2022-2024 | Accolade Sr, Watchman Flx |
| Medtronic Vascular, INC. | $93.18 | 2019 | |
| Sanofi-Aventis U.S. LLC | $84.89 | 2021-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.25 | 2019-2024 | Lifevest |
| Bayer Healthcare Pharmaceuticals INC. | $72.77 | 2022 | |
| Heartflow, INC. | $61.98 | 2019-2023 | Ffrct |
| Merck Sharp & Dohme LLC | $44.73 | 2022-2023 | Verquvo, Lagevrio |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $36.48 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $35.61 | 2022-2023 | Arcalyst |
| Tactile Systems Technology INC | $22.12 | 2024 | Entre Plus, Flexitouch Plus |
| Agepha Pharma Fz LLC | $20.26 | 2024 | Lodoco |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.88 | 2023 | Jardiance |
| Preventice Services, LLC | $17.56 | 2019 | |
| Pfizer INC. | $17.11 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $16.17 | 2024 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $14.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Raizner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.